2Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)] 3Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11-fold increase in exposure) Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs EE = ethinyl estradiol, NG = norgestrel, QD= Once daily 1 Clinically significant pharmacodynamic effects [see Drug Interactions (7.3)] 2Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure) Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins
We offer specially formulated supplements that help burn excess fat and support healthy weight loss
J Neurosci Res 47:9097 Rogers SA (2003) Lipoic acid as a potential first agent for protection from mycotoxins and treatment of mycotoxicosis
The peptides mechanism appears to preferentially mobilize fat from metabolically active depots while preserving muscle tissue, creating favorable body recomposition rather than non-selective weight loss
